What is HC Wainwright’s Forecast for Evotec FY2024 Earnings?

Evotec SE (NASDAQ:EVO) – Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Evotec in a note issued to investors on Thursday, November 7th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.51) per share for the year, down from their previous forecast of ($0.42). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Evotec’s Q4 2024 earnings at ($0.04) EPS, FY2026 earnings at $0.23 EPS and FY2027 earnings at $0.47 EPS.

Several other research firms have also recently commented on EVO. Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $15.00 to $6.00 in a report on Monday, July 29th. Jefferies Financial Group downgraded shares of Evotec from a “buy” rating to a “hold” rating and lowered their target price for the stock from $8.70 to $3.80 in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.93.

Evotec Stock Up 17.9 %

Shares of Evotec stock opened at $4.87 on Monday. The business has a 50-day simple moving average of $3.54 and a 200-day simple moving average of $4.20. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.73. Evotec has a one year low of $2.85 and a one year high of $12.00.

Institutional Investors Weigh In On Evotec

A number of institutional investors and hedge funds have recently bought and sold shares of EVO. Novo Holdings A S purchased a new stake in Evotec in the second quarter valued at approximately $71,183,000. Cetera Advisors LLC purchased a new stake in Evotec in the 1st quarter valued at $188,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Evotec during the 2nd quarter worth $87,000. DCF Advisers LLC grew its position in Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in Evotec in the third quarter valued at $512,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.